Vaxato 10 mg 10 tablets
Liptis Pharmaceuticals Factory
Liptis Pharmaceuticals Factory
Compound
rivaroxaban (micronized) 10 mg
Auxiliary components
Microcrystalline cellulose, mannitol, croscarmellose sodium, sodium lauryl sulfate, anhydrous citric acid, magnesium stearate.
Properties
Rivaroxaban is a highly selective direct factor Xa inhibitor with relatively high oral bioavailability. Activation of factor X to form factor Xa (FXa) via intrinsic and extrinsic pathways plays a central role in the coagulation cascade. FXa directly converts prothrombin to thrombin via the prothrombinase complex, and this reaction ultimately leads to fibrin clot formation and thrombin activation of platelets. Due to the amplification nature of the coagulation cascade, one factor Xa molecule promotes the formation of more than 1000 thrombin molecules.
Indications
– prevention of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation;
-treatment of deep vein thrombosis and pulmonary embolism and prevention of recurrence of DVT and PE.
Mode of application
inside.
The drug 10 mg and 20 mg should be taken with meals.
Contraindications
– hypersensitivity to rivaroxaban or any auxiliary components of the drug;
– clinically significant active bleeding; injuries or conditions associated with an increased risk of major bleeding;
– recent trauma to the brain or spinal cord, surgery on the brain, spinal cord or eyes, intracranial hemorrhage, diagnosed or suspected esophageal varicose veins, arteriovenous malformations, vascular aneurysms or vascular pathology of the brain or spinal cord; – concomitant therapy with any other anticoagulants;
– liver disease with coagulopathy, which causes a clinically significant risk of bleeding;
– severe degree of impaired renal function (CC <15 ml / min);
-pregnancy;
– period of breastfeeding;
-children and adolescents up to 18 years;
– congenital lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Precautionary measures
As with other anticoagulants, patients receiving Vaxato should be closely monitored for signs of bleeding.
In the event of severe bleeding, Vaxato should be discontinued.
Side effects
From the blood and lymphatic system
Anemia (including relevant laboratory parameters).
From the immune system
Allergic reaction, allergic dermatitis.
From the nervous system
Dizziness, headache.
From the side of the organ of vision
Hemorrhage in the eye (including hemorrhage in the conjunctiva).
From the vascular side
Pronounced decrease in blood pressure, hematoma.
From the respiratory system, chest organs
Nosebleeds, hemoptysis.
From the digestive system
Bleeding gums, gastrointestinal bleeding (including rectal bleeding), abdominal pain, dyspepsia, nausea, constipation, diarrhea, vomiting.
From the skin and subcutaneous tissues
Skin itching (including infrequent cases of generalized itching), skin rash, ecchymosis, skin and subcutaneous hemorrhages.
Storage
Store at a temperature not exceeding 30 degrees.
Package
The cardboard box contains 10 tablets, paper instructions.